Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition
Executive Summary
Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.
You may also be interested in...
Medical Aesthetics: Key Players In A Largely Untapped Market
Medical aesthetics is a growing, but largely untapped biopharma niche with unique consumer marketing and doctor relationship-building strategies where key players have honed their skills for many years. Allergan's blockbuster Botox dominates, but competitors are gaining ground.
Scrip Asks… What's The Current Climate For Deal-Making? (Part 1)
Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – first up are responses from small biotechs.
Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.